Professor Park Yeon-hee of the Hematology and Oncology department at Samsung Medical Center who recently spoke at the press conference held to celebrate the launch of ‘Enhertu’ in Korea said, “I have never seen such data in breast cancer.” This goes to show the superior efficacy of Enhertu in breast cancer. She added, “During the Enhertu clinical trial, I was inspected by the Ministry of Food and Drug Safety due to the large number of patients enrolling in the trial. And during inspections, my sole concern was, ‘what if a fault I didn’t know about is found that disallows patients from using the drug?’ This was how essential Enhertu is to the patients.”

At the American Society of Clinical Oncol